一例胰岛素瘤伴低血糖患者，使用兰瑞肽治疗比奥曲肽效果更佳。
A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide.
作者信息
Yamaoka Keiko, Nagashima Shuichi, Okada Nobukazu, Sawayama Nagisa, Saito Shinsuke, Takahashi Manabu, Okada Kenta, Endo Kazuhiro, Koizumi Masaru, Sasanuma Hideki, Ebihara Ken, Kasajima Atsuko, Fukushima Noriyoshi, Sata Naohiro, Ishibashi Shun
机构信息
Division of Endocrinology and Metabolism Department of Medicine Jichi Medical University Shimotsuke Japan.
Department of Surgery Jichi Medical University Shimotsuke Japan.
出版信息
Clin Case Rep. 2021 May 19;9(5):e04118. doi: 10.1002/ccr3.4118. eCollection 2021 May.
Long-acting somatostatin analogs, including lanreotide slow release (LAN-SR) and octreotide long-acting release (OCT-LAR), can improve hypoglycemia in insulinoma. LAN-SR may be more beneficial in some patients with insulinoma than OCT-LAR.
长效生长抑素类似物，包括缓释兰瑞肽（LAN-SR）和长效奥曲肽（OCT-LAR），可改善胰岛素瘤患者的低血糖症状。在某些胰岛素瘤患者中，LAN-SR可能比OCT-LAR更有益。
Zotero 插件